Conference: 2008 International PHA Conference and Scientific Sessions
Release Date: 06.22.2008
Presentation Type: Slide Shows
Download Adobe Acrobat
The Division of Lung Diseases, NHLBI supports a comprehensive portfolio of more than ninety grants on pulmonary hypertension (PH). These projects include: basic cell and molecular biology of PH; identification of the gene(s) and gene mutations, which predispose a person to develop PH; and multi-disciplinary program projects combining basic and patient-based research. Two new Specialized Centers of Clinically Oriented Research (SCCOR) in Pulmonary Vascular Disease were funded in 2007. These programs are collaborative research projects, integrating both basic science approaches to study mechanisms, and clinical research for adult and pediatric PH. New methods of treating PH and better diagnostic methods are being investigated in these SCCOR programs. A clinical trial in PH is underway to examine the effects of an anti-inflammatory and cholesterol-lowering drug (simvastatin) with or without aspirin as a new treatment for PH.
The Institute encourages submission of new applications in both basic and clinical research for PH, and continues the collaboration with the Pulmonary Hypertension Association to support new clinical investigators pursuing research in PH. Finally, a Program Announcement on, “Right Heart Function in Health and Disease,”encourages research on the interaction of the right ventricle and the lungs, and the mechanisms of right heart failure associated with PAH and other chronic lung diseases.
The research effort in pulmonary hypertension is vibrant and exciting. Future research opportunities are many and include understanding how immune system involvement might affect development of PH, investigations of lung endothelial proliferation, continued research on genetic factors influencing PH and exploration of novel therapeutic approaches. New developments at NIH and NHLBI will also be presented.